Skip to main content

Commodore Capital LP

SEC CIK
0001831942
Latest filing
Aug 14, 2026

Holdings in Q1 2023

Holdings as of Mar 31, 2023, filed May 15, 2023. Long positions only; changes compare share counts with Q4 2022.

Institution overview
Positions
32
−3 vs. Q4 2022
Portfolio value
$656.8M
−$6.71M (−1.0%) vs. Q4 2022
Filed
May 15, 2023
SEC
Holdings of Commodore Capital LP in Q1 2023
SecurityClassSharesValue% of portfolioShare changeActionHistory
XENEXenon Pharmaceuticals Inc.COM1,845,000$66.0M10.1%+185,889+11.2%AddedHistory
VRDNViridian Therapeutics, Inc.COM2,189,659$55.7M8.5%+169,493+8.4%AddedHistory
MRUSMerus N.V.COM2,950,000$54.3M8.3%+217,433+8.0%AddedHistory
COGTCogent Biosciences, Inc.COM4,772,421$51.5M7.8%+452,481+10.5%AddedHistory
Bellus Health Inc New07987C204COM NEW6,579,359$47.4M7.2%+1,275,802+24.1%Added–
AMAMAmbrx Biopharma Cayman, Inc.SPONSORED ADS4,803,447$42.8M6.5%+4,803,447NewHistory
ELVNEnliven Therapeutics, Inc.COM1,731,365$37.9M5.8%+1,731,365NewHistory
AKROAkero Therapeutics, Inc.COM790,000$30.2M4.6%+252,924+47.1%AddedHistory
NUVLNuvalent, Inc.COM1,075,000$28.0M4.3%+161,379+17.7%AddedHistory
IMVTImmunovant, Inc.COM1,440,999$22.3M3.4%+290,494+25.2%AddedHistory
VERAVera Therapeutics, Inc.CL A2,824,029$21.9M3.3%+2,824,029NewHistory
SNDXSyndax Pharmaceuticals IncCOM853,884$18.0M2.7%+165,439+24.0%AddedHistory
CLDXCelldex Therapeutics, Inc.COM NEW495,823$17.8M2.7%00.0%UnchangedHistory
CBAYCymaBay Therapeutics, Inc.COM2,025,000$17.7M2.7%−3,713,500−64.7%ReducedHistory
CABACabaletta Bio, Inc.COM1,835,000$15.2M2.3%+824,641+81.6%AddedHistory
KURAKura Oncology, Inc.COM1,204,958$14.7M2.2%+105,551+9.6%AddedHistory
ARWRArrowhead Pharmaceuticals, Inc.COM575,000$14.6M2.2%+112,889+24.4%AddedHistory
CELCCelcuity Inc.COM1,390,772$14.3M2.2%+62,820+4.7%AddedHistory
RXDXPrometheus Biosciences, Inc.COM127,156$13.6M2.1%00.0%UnchangedHistory
ALPNAlpine Immune Sciences, Inc.COM1,325,000$10.2M1.6%00.0%UnchangedHistory
DAWNDay One Biopharmaceuticals, Inc.Stock739,661$9.89M1.5%00.0%UnchangedHistory
Avidity Biosciences, Inc.05370A108COM590,705$9.07M1.4%00.0%Unchanged–
ENTAEnanta Pharmaceuticals IncCOM217,253$8.79M1.3%−6,241−2.8%ReducedHistory
ALLKAllakos Inc.COM1,900,000$8.46M1.3%+256,500+15.6%AddedHistory
PCVXVaxcyte, Inc.COM200,000$7.50M1.1%+26,519+15.3%AddedHistory
ACRSAclaris Therapeutics, Inc.COM635,000$5.14M0.8%−1,245,286−66.2%ReducedHistory
THRDThird Harmonic Bio, Inc.COM993,294$4.09M0.6%00.0%UnchangedHistory
ADVMAdverum Biotechnologies, Inc.COM5,000,000$3.59M0.5%+5,000,000NewHistory
KALVKalVista Pharmaceuticals, Inc.COM312,553$2.46M0.4%00.0%UnchangedHistory
RZLTRezolute, Inc.COM NEW898,267$1.72M0.3%−311,733−25.8%ReducedHistory
ABOSAcumen Pharmaceuticals, Inc.COM400,000$1.62M0.2%−98,315−19.7%ReducedHistory
DBVTDBV Technologies S.A.SPONSORED ADR92,687$156.6K<0.1%00.0%UnchangedHistory

Sold out since Q4 2022 (7)

Positions held at the end of Q4 2022 that are gone from this filing.

Positions of Commodore Capital LP sold out since Q4 2022
SecurityClassShares in Q4 2022Value in Q4 2022% of portfolio in Q4 2022History
ACLXArcellx, Inc.COMMON STOCK591,437$18.3M2.8%History
FDMT4D Molecular Therapeutics, Inc.COM598,385$13.3M2.0%History
ELVNEnliven Therapeutics, Inc.COM2,494,794$10.2M1.5%History
ETNB89bio, Inc.COM758,244$9.65M1.5%History
KPTIKaryopharm Therapeutics Inc.COM1,935,609$6.58M1.0%History
LRMRLarimar Therapeutics, Inc.COM750,000$3.10M0.5%History
IMUXImmunic, Inc.COM1,800,000$2.52M0.4%History